Thus, our study links various p53 mutations to deregulation of ASS1 in clinical samples for the first time, and also provides an explanation for the poor overall survival seen in the non‐squamous NSCLC patient cohort. This evidence concerns the gene ASS1 and non-small cell lung carcinoma.